Please assess the completion status of the following clinical trial:

Trial Title: Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion~* Autologous PBSC transplant patient~* English-speaking~* Planned cryopreserved PBSC infusion at the SCCA outpatient clinic~Exclusion~* History of prior autologous transplant~* Non-English-speaking~* Planned cryopreserved PBSC infusion at the UWMC inpatient unit~* Infusion of cryopreserved PBSC that are thawed and washed to remove DMSO prior to infusion~* Allergy or adverse reaction to ondansetron

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ondansetron therapy (Type: EXPERIMENTAL): Patients receive ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).